Less than one-third of subjects were receiving an angiotensin converting enzyme inhibitor at baseline, although this rose to around 40% by the end of follow-up.

• 不到三分之一的受试者接受一种血管紧张素转换酶抑制剂作为基础用药，尽管在结束随访时接近40%25。